Core A: University of Kentucky Alzheimer's Disease Core Center
核心 A:肯塔基大学阿尔茨海默病核心中心
基本信息
- 批准号:10459466
- 负责人:
- 金额:$ 27.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AdministratorAlzheimer&aposs DiseaseAlzheimer&aposs Disease Core CenterAlzheimer&aposs disease related dementiaAutopsyBiologicalBrainBrain PathologyCapitalCaregiversCessation of lifeClinicalCognitiveCognitive agingCollaborationsCommunicationCommunitiesDementiaDevelopmentDoctor of PhilosophyElderlyEnsureEnvironmentEtiologyFosteringFoundationsGoalsHeterogeneityHuman ResourcesHuman VolunteersImpaired cognitionIndividualInfrastructureKentuckyKnowledgeLeadershipModalityMonitorNeurosciencesOccupational activity of managing financesPathogenicityPathologyPatientsPreventionResearchResearch ActivityResearch PersonnelResourcesRiskRisk FactorsScienceStrategic PlanningStructureSystemTissuesTraining and EducationTranslational ResearchUnited StatesUniversitiesaccurate diagnosticsbeneficiarycognitive developmentcohortcomorbiditydiagnostic strategydisease heterogeneityeffective therapyinnovationmeetingsmultidisciplinarynovel therapeuticspre-clinicalpreventprogramssuccesstraining opportunitytreatment strategyvolunteer
项目摘要
Project Summary/Abstract: Administrative Core
The ultimate goal of the UK-ADRC is to catalyze innovative and outstanding AD research while ensuring a
more rapid rate of progress toward new therapies to delay or prevent AD, so that our human volunteers,
patients and caregivers become the beneficiaries of our advances in knowledge. The Administrative Core
provides the foundation, infrastructure, leadership, overall direction, strategic planning, and integration of all
ADRC components to more rapidly achieve this goal and advance our overall theme: “Transitions from Normal
to Late-Life Multi-Etiology Dementia”. This theme builds on our traditional strengths in defining mechanisms
underlying the early changes that occur in individuals as they transition through the cognitive continuum, risk
factors associated with these cognitive states, and how mixed pathology and co-morbidities influence risk and
progression. Two historically outstanding resources of the UK-ADRC that enable research relevant to this
theme are: 1) a strong autopsy program providing clinical-neuropathological correlation and very short (2-4 hrs)
postmortem interval (PMI) research material, and 2) a unique, continuously replenished group of ~500
cognitively intact subjects followed longitudinally, together with another ~300 initially normal individuals who
transition to pre-MCI, MCI or dementia, and all committed to brain autopsy upon death. These signature
resources have contributed to our becoming one of the premier centers defining pathogenic mechanisms
underlying the transitions from normal cognitive aging to the earliest stages of cognitive impairment. The UK-
ADRC functions in a multidisciplinary, integrated, collaborative and supportive team science environment that
catalyzes high-quality AD research within the UK community, region, nation, and beyond. We will continue to
provide the infrastructure, resources and intellectual capital to enhance transdisciplinary research and scientific
interactions, develop new collaborations and partnerships, contribute to national initiatives, and offer innovative
education and training opportunities in the basic and clinical neurosciences. An effective Administrative Core is
essential for transforming our goals into accomplishments. Therefore, the Core will continue to support the
ability of our UK-ADRC to accomplish its goals, and to promote the NAPA research implementation milestones
and goals, through the following specific aims.
Aim 1: Provide leadership, administrative structure, coordination, and financial management to ensure optimal
resource utilization to meet the overall goals of the UK-ADRC.
Aim 2: Promote and catalyze clinical/translational research activities, maximize interactions with other
departments and centers, and foster new avenues of innovative research.
Aim 3: Solicit, review, select, and monitor the Developmental Projects.
Aim 4: Contribute to and interact with other ADRCs and other national collaborative activities and increase
visibility in the local and national community.
项目概要/摘要:行政核心
UK-ADRC的最终目标是促进创新和优秀的AD研究,同时确保
以更快的速度发展新的治疗方法来延缓或预防AD,这样我们的人类志愿者,
病人和护理人员成为我们知识进步的受益者。行政核心
提供基础、基础设施、领导、总体方向、战略规划和所有
ADRC组件,以更快地实现这一目标,并推进我们的整体主题:“从正常的过渡
多病因老年痴呆症”这一主题建立在我们在确定机制方面的传统优势之上
在个体经历认知连续体的过渡过程中,
与这些认知状态相关的因素,以及混合病理和共病如何影响风险和
进展英国ADRC的两个历史上杰出的资源,使相关的研究,
主题是:1)强有力的尸检程序提供临床-神经病理学相关性和非常短的时间(2-4小时)
死后间隔(PMI)研究材料,和2)一个独特的,不断补充组约500
认知完整的受试者与另外300名最初正常的个体一起纵向跟踪,
向轻度认知障碍前期、轻度认知障碍或痴呆过渡,并在死亡后进行脑尸检。这些签名
我们的资源使我们成为确定致病机制的主要中心之一
从正常认知老化到认知障碍的早期阶段的过渡。英国-
ADRC在多学科,综合,协作和支持团队科学环境中发挥作用,
促进英国社区,地区,国家和其他地区的高质量AD研究。我们将继续
提供基础设施、资源和智力资本,以加强跨学科研究和科学
互动,发展新的合作和伙伴关系,促进国家倡议,并提供创新的
基础和临床神经科学的教育和培训机会。一个有效的行政核心是
这是将我们的目标转化为成就的关键。因此,核心将继续支持
我们的英国-ADRC实现其目标的能力,并促进国家适应行动方案研究实施里程碑
通过以下具体目标实现目标。
目标1:提供领导、行政结构、协调和财务管理,以确保最佳
资源利用,以满足英国ADRC的总体目标。
目标2:促进和催化临床/转化研究活动,最大限度地与其他研究人员进行互动
部门和中心,并促进创新研究的新途径。
目标3:征求、审查、选择和监督发展项目。
目标4:为其他发展成果中心和其他国家合作活动作出贡献并与其互动,
在当地和国家社区的知名度。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LINDA J VAN ELDIK其他文献
LINDA J VAN ELDIK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LINDA J VAN ELDIK', 18)}}的其他基金
GMP Production and Extended Toxicology of an Oral Formulation Drug for Alzheimer's Disease
治疗阿尔茨海默病的口服制剂药物的 GMP 生产和扩展毒理学
- 批准号:
10624841 - 财政年份:2022
- 资助金额:
$ 27.88万 - 项目类别:
Portable and modular UDS Data Collection software to increase collaboration and engagement of Alzheimer’s Disease Research Center research software engineers
便携式模块化 UDS 数据收集软件,可增强阿尔茨海默病研究中心研究软件工程师的协作和参与
- 批准号:
10608722 - 财政年份:2021
- 资助金额:
$ 27.88万 - 项目类别:
Core A: University of Kentucky Alzheimer's Disease Core Center
核心 A:肯塔基大学阿尔茨海默病核心中心
- 批准号:
10261962 - 财政年份:2021
- 资助金额:
$ 27.88万 - 项目类别:
University of Kentucky Alzheimer's Disease Research Center
肯塔基大学阿尔茨海默病研究中心
- 批准号:
10662314 - 财政年份:2021
- 资助金额:
$ 27.88万 - 项目类别:
Core G: University of Kentucky Alzheimer's Disease Core Center
核心 G:肯塔基大学阿尔茨海默病核心中心
- 批准号:
10662371 - 财政年份:2021
- 资助金额:
$ 27.88万 - 项目类别:
Core A: University of Kentucky Alzheimer's Disease Core Center
核心 A:肯塔基大学阿尔茨海默病核心中心
- 批准号:
10662339 - 财政年份:2021
- 资助金额:
$ 27.88万 - 项目类别:
Core G: University of Kentucky Alzheimer's Disease Core Center
核心 G:肯塔基大学阿尔茨海默病核心中心
- 批准号:
10459472 - 财政年份:2021
- 资助金额:
$ 27.88万 - 项目类别:
University of Kentucky Alzheimer's Disease Research Center
肯塔基大学阿尔茨海默病研究中心
- 批准号:
10459464 - 财政年份:2021
- 资助金额:
$ 27.88万 - 项目类别:
University of Kentucky Alzheimer's Disease Research Center
肯塔基大学阿尔茨海默病研究中心
- 批准号:
10261961 - 财政年份:2021
- 资助金额:
$ 27.88万 - 项目类别:
Core G: University of Kentucky Alzheimer's Disease Core Center
核心 G:肯塔基大学阿尔茨海默病核心中心
- 批准号:
10261968 - 财政年份:2021
- 资助金额:
$ 27.88万 - 项目类别: